Fax: (412) 641-2296
Final 5-year results of Z-FAST trial†
Adjuvant Zoledronic Acid Maintains Bone Mass in Postmenopausal Breast Cancer Patients Receiving Letrozole
Article first published online: 10 OCT 2011
Copyright © 2011 American Cancer Society
Volume 118, Issue 5, pages 1192–1201, 1 March 2012
How to Cite
Brufsky, A. M., Harker, W. G., Beck, J. T., Bosserman, L., Vogel, C., Seidler, C., Jin, L., Warsi, G., Argonza-Aviles, E., Hohneker, J., Ericson, S. G. and Perez, E. A. (2012), Final 5-year results of Z-FAST trial. Cancer, 118: 1192–1201. doi: 10.1002/cncr.26313
Study results were presented in part at the 32nd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 9-13, 2009 (Abstract 4083).
- Issue published online: 17 FEB 2012
- Article first published online: 10 OCT 2011
- Manuscript Accepted: 2 MAY 2011
- Manuscript Revised: 11 APR 2011
- Manuscript Received: 19 JAN 2011
- 4National Comprehensive Cancer Network. The NCCN Clinical Practice Guidelines in Oncology Breast Cancer (V. 2.2010). Available at: www.nccn.org. Accessed on April 14, 2010.
- 12Package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2009..
- 13Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST study results. Cancer. 2008; 112: 1001-1010., , , et al.
- 17for the Austrian Breast and Colorectal Cancer Study Group (ABCSG). Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol. 2008; 9: 840-849., , , et al
- 19Zoledronic acid as adjuvant therapy for women with early stage breast cancer and disseminated tumor cells in bone marrow [abstract]. J Clin Oncol. 2008; 26( suppl 15S): 20s. Abstract 559., , , et al.
- 20Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients. Presented at: 31st Annual San Antonio Breast Cancer Symposium; December 10-14, 2008; San Antonio, Tex. Abstract 2048., , , et al.
- 23Effect of zoledronate on persisting isolated tumor cells in the bone marrow of patients without recurrence of early breast cancer. Presented at: 30th Annual San Antonio Breast Cancer Symposium; December 13-16, 2007; San Antonio, Tex. Abstract 511., , , et al.
- 27Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastases in nude mice. Oncol Rep. 2008; 20: 582-587., , , et al.
- 34Adjuvant treatment with zoledronic acid in stage II/III breast cancer. The AZURE trial (BIG 01/04). Presented at: 33rd Annual San Antonio Breast Cancer Symposium; December 8-12, 2010; San Antonio, Tex. Abstract S4–5., , , et al.
- 35http://www.medscape.com/viewarticle/733978. Accessed April 5, 2011.. AZURE: Zoledronic acid effect on breast cancer is complicated. Available at: